This is a preview of subscription content, log in via an institution to check access.
References
Wallis EJ, Ramsay LE, Hettiarachchi J. Combined inhibition of neutral endopeptidase and angiotensin-converting enzyme by sampatrilat in essential hypertension. Clin Pharmacol Ther 1998; 64: 439–49
Barclay PL, Barnes PE, Cussans NJ, et al. UK-81,252: a novel dual inhibitor of neutral endopeptidase and angiotensin-converting enzyme. 7th European Meeting on Hypertension; 1995 Jun 9; Milan, 15–6
Brearley CJ, Allen MJ, Grimwood VC, et al. The pharmacodynamic effects of UK-81,252: a novel dual inhibitor of neutral endopeptidase and angiotensin-converting enzyme in human essential hypertension. 7th European Meeting on Hypertension; 1995 Jun 9–12; Milan, 27
Rights and permissions
About this article
Cite this article
Sampatrilat. Drugs in R&D 1, 352–353 (1999). https://doi.org/10.2165/00126839-199901040-00018
Published:
Issue Date:
DOI: https://doi.org/10.2165/00126839-199901040-00018